Viewing Study NCT05259293


Ignite Creation Date: 2025-12-25 @ 1:01 AM
Ignite Modification Date: 2025-12-25 @ 11:15 PM
Study NCT ID: NCT05259293
Status: COMPLETED
Last Update Posted: 2024-09-19
First Post: 2021-12-07
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Characteristics of Pneumothorax Associated With Transthoracic Percutaneous Lung Biopsy in Standard of Care
Sponsor: Centre Hospitalier Universitaire de Besancon
Organization:

Study Overview

Official Title: Characteristics of Pneumothorax Associated With Transthoracic Percutaneous Lung Biopsy in Standard of Care: a Retrospective Study in 6 Centers
Status: COMPLETED
Status Verified Date: 2023-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PNOrate
Brief Summary: The number of lung biopsies has increased steadily in recent years. Pneumothorax is the most common complication of a lung biopsy and can occur during the procedure, immediately after the procedure or within a few hours (delayed pneumothorax). The incidence of pneumothorax in the literature is very different from one study to another: it has been reported to be from 9 to 54% in patients undergoing percutaneous transthoracic needle biopsy. This difference of incidence could be explained by the absence of consensus for the definition of an iatrogenic pneumothorax.

The characteristics of pneumothorax and the management of patients with iatrogenic pneumothorax will be evaluated in different centres in a retrospective manner. This study will contribute to refining the criteria for defining pneumothorax occurring during lung biopsy and will provide a better understanding of the condition and its management.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: